EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

PSMD12 Overexpression Promotes Lung Adenocarcinoma Progression via Ubiquitin–Proteasome Pathway Dysregulation

Yuya Ono iD, Hajime Otsu, Takaaki Masuda, Keisuke Kosai, Shohei Shibuta, Kosuke Hirose, Takashi Ofuchi, Yuki Ando, Koto Kawata, Yasuo Tsuda, Yusuke Yonemura, Taro Tobo und 3 weitere

Cancer Science · 2026

DOI: 10.1111/cas.70290 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2026. Verfasst von Yuya Ono und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Hauptthemen laut MEDLINE: Lung Neoplasms, Proteasome Endopeptidase Complex, Adenocarcinoma of Lung, Ubiquitin. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the Princess Takamatsu Cancer Research Fund, the Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Scientific Research, the Takeda Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung adenocarcinoma (LUAD) is one of the most common cancers and a leading cause of cancer‐related mortality worldwide, highlighting the need for novel therapeutic strategies. Proteasome 26S Subunit, Non‐ATPase 12 (PSMD12), a component of the proteasomal 19S regulatory particle, is associated with tumorigenesis; however, its role in LUAD remains poorly understood. Integrative bioinformatic analysis of The Cancer Genome Atlas (TCGA) and other publicly available LUAD datasets identified PSMD12 as a candidate driver gene on chromosome 17q, a region frequently amplified in LUAD. Clinicopathological and prognostic analyses revealed that PSMD12 was significantly upregulated in tumor tissues because of DNA copy number gain. High PSMD12 expression was associated with poor prognosis and advanced pathological stages. Gene set enrichment analysis of TCGA LUAD dataset demonstrated that samples with high PSMD12 expression were enriched for cell cycle–related pathways. Using CRISPR‐Cas9–mediated PSMD12 knockout and lentivirus‐mediated overexpression models, we demonstrated that PSMD12 promoted tumor cell proliferation by accelerating the G2/M cell cycle transition in vitro, and xenograft experiments confirmed its tumor‐promoting effect in vivo. Mechanistically, PSMD12 overexpression reduced the ubiquitination of CDK1, a key regulator of mitotic entry. Cycloheximide chase and MG132 assays confirmed that PSMD12 stabilized CDK1 by inhibiting proteasome‐mediated degradation. In conclusion, we identified PSMD12 as a novel driver gene and prognostic biomarker of LUAD. PSMD12 promoted LUAD progression by modulating CDK1 ubiquitination and enhancing cell cycle progression. These findings suggest that PSMD12 is a promising molecular target for future LUAD therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsProteasome Endopeptidase ComplexAdenocarcinoma of LungUbiquitinHumansAnimalsGene Expression Regulation, NeoplasticPrognosisDisease ProgressionCell Line, TumorCell ProliferationMiceFemaleUbiquitinationMaleCDC2 Protein KinaseSignal TransductionUp-RegulationMice, Nude

Stichwörter der Autor:innen

CDK1cell cyclelung adenocarcinomanon‐ATPase 12 (PSMD12)proteasome 26S subunitubiquitin proteasome system (UPS)

Substanzen

Proteasome Endopeptidase ComplexUbiquitinCDC2 Protein Kinase

Autor:innen und Institutionen

  • Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Department of Surgery, Kyushu University Beppu Hospital, Beppu, Japan.
  • Department of Breast and Endocrine Surgery, Kochi Medical School, Kochi University, Nankoku, Japan.
  • Department of Pathology, Kyushu University Beppu Hospital, Beppu, Japan.
  • Department of Thoracic Surgery, Kyushu University Hospital, Fukuoka, Japan.

ORCID-Profile: Yuya Ono, Koshi Mimori

Förderung

  • the Princess Takamatsu Cancer Research Fund
  • the Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Scientific Research
  • the Takeda Science Foundation
  • OITA Cancer Research Foundation
  • Takeda Science Foundation

Zitieren

APA

Ono, Y., Otsu, H., Masuda, T., Kosai, K., Shibuta, S., Hirose, K., Ofuchi, T., Ando, Y., Kawata, K., Tsuda, Y., Yonemura, Y., Tobo, T., Takenaka, T., Yoshizumi, T., & Mimori, K. (2026). PSMD12 Overexpression Promotes Lung Adenocarcinoma Progression via Ubiquitin–Proteasome Pathway Dysregulation. Cancer Science. https://doi.org/10.1111/cas.70290

Vancouver

Ono Y, Otsu H, Masuda T, Kosai K, Shibuta S, Hirose K, et al. PSMD12 Overexpression Promotes Lung Adenocarcinoma Progression via Ubiquitin–Proteasome Pathway Dysregulation. Cancer Science. 2026. doi:10.1111/cas.70290

BibTeX
@article{Ono2026,
  author = {Ono, Yuya and Otsu, Hajime and Masuda, Takaaki and Kosai, Keisuke and Shibuta, Shohei and Hirose, Kosuke and Ofuchi, Takashi and Ando, Yuki and Kawata, Koto and Tsuda, Yasuo and Yonemura, Yusuke and Tobo, Taro and Takenaka, Tomoyoshi and Yoshizumi, Tomoharu and Mimori, Koshi},
  title = {PSMD12 Overexpression Promotes Lung Adenocarcinoma Progression via Ubiquitin–Proteasome Pathway Dysregulation},
  journal = {Cancer Science},
  year = {2026},
  doi = {10.1111/cas.70290}
}
Kostenlos starten →